Sat, May 17, 2025
Fri, May 16, 2025
Thu, May 15, 2025
Wed, May 14, 2025
Tue, May 13, 2025
[ Tue, May 13th ]: WSAZ
Summer science experiments

Intellia cuts 27% of staff, in the latest wave of gene-editing layoffs

  Copy link into your clipboard //science-technology.news-articles.net/content/2 .. -in-the-latest-wave-of-gene-editing-layoffs.html
  Print publication without navigation Published in Science and Technology on by STAT
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning! Ready for JPM?
The article from STAT News dated January 10, 2025, discusses several significant developments in the biotech industry. Intellia Therapeutics announced positive results from a Phase 1/2 trial of its CRISPR-based therapy for transthyretin amyloidosis, showing significant reduction in disease-causing protein levels. Pfizer and Bristol Myers Squibb are reportedly in talks to collaborate on a new cancer immunotherapy, aiming to combine their respective assets to enhance treatment efficacy. Eli Lilly reported successful outcomes from a late-stage trial of its Alzheimer's drug, which demonstrated a slowdown in cognitive decline. Additionally, venture capital firm Andreessen Horowitz (a16z) launched a new $750 million fund dedicated to biotech startups, signaling strong investor confidence in the sector's future. These updates highlight ongoing advancements and investments in gene editing, cancer treatment, neurodegenerative diseases, and biotech innovation.

Read the Full STAT Article at:
[ https://www.statnews.com/2025/01/10/biotech-news-intellia-pfizer-bristol-meyers-squibb-eli-lilly-cancer-a16z-the-readout/ ]